Search hospitals
>
Texas
>
Houston
M D Anderson Cancer Center
Claim this profile
Houston, Texas 77030
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
6030 reported clinical trials
470 medical researchers
Summary
M D Anderson Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. M D Anderson Cancer Center is involved with conducting 6,030 clinical trials across 2,169 conditions. There are 470 research doctors associated with this hospital, such as Najat C. Daw, Sarina Piha-Paul, MD, Timothy Yap, and Funda Meric-Bernstam, MD.
Area of expertise
Cancer
M D Anderson Cancer Center has run 1217 trials for Cancer. Some of their research focus areas include:
Breast Cancer
M D Anderson Cancer Center has run 711 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Najat C. Daw
M D Anderson Cancer Center
6 years of reported clinical research
Sarina Piha-Paul, MD
MD Anderson Cancer Center
8 years of reported clinical research
Timothy Yap
M D Anderson Cancer Center
5 years of reported clinical research
Funda Meric-Bernstam, MD
M D Anderson Cancer Center
16 years of reported clinical research
Clinical Trials running at M D Anderson Cancer Center
Acute Myeloid Leukemia
Lung Cancer
Myelodysplastic Syndrome
Breast Cancer
Cancer
Acute Myelogenous Leukemia
Non-Hodgkin's Lymphoma
Esophageal Adenocarcinoma
Colorectal Cancer
Chronic Myeloid Leukemia
Venetoclax + Azacitidine
for Acute Myeloid Leukemia
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Recruiting
3 awards
Phase 2
23 criteria
Chemotherapy Combination
for Leukemia
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a antitumor drug, called calicheamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers calicheamicin to kill them. Colony-stimulating factors, such as filgrastim-sndz, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride may kill more cancer cells.
Recruiting
3 awards
Phase 2
Azacitidine + Venetoclax + Gilteritinib
for Leukemia
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment (refractory). Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine, venetoclax, and gilteritinib may work better compared to azacitidine and venetoclax alone in treating patients with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndrome/myeloproliferative neoplasm.
Recruiting
3 awards
Phase 1 & 2
10 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at M D Anderson Cancer Center?
M D Anderson Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. M D Anderson Cancer Center is involved with conducting 6,030 clinical trials across 2,169 conditions. There are 470 research doctors associated with this hospital, such as Najat C. Daw, Sarina Piha-Paul, MD, Timothy Yap, and Funda Meric-Bernstam, MD.
Where is M D Anderson Cancer Center located?
**MD Anderson Cancer Center - Houston, Texas** - **Address:** 6901 Bertner Ave, Houston, Texas - For directions, take I-69 or US-59 South to reach the center. - For real-time driving directions to the MD Anderson Mays Clinic, use the Waze app with the address: 1220 Holcombe Blvd.
Who should I call to ask about financial aid or insurance network?
**M D Anderson Cancer Center Financial Assistance and Insurance Information** - **Insurance Information:** For general insurance inquiries, visit the MD Anderson Cancer Center website or call 877-632-6789 for specific questions. - **Financial Assistance Program:** Eligible cancer patients can benefit from a financial assistance program. Requirements include residency and financial eligibility. - **Financial Evaluation and Advocacy:** Schedule a financial evaluation by calling 1.844.MDA.BAPTIST (1.844.632.2278). Financial advocates are available to assist with fulfilling financial responsibilities and accessing government medical assistance programs. - **Flexible Payment Plans and Pharmaceutical Assistance:** Payment plans may be arranged based on financial status. For assistance with the cost of chemotherapy treatments, contact a patient financial advocate. - **Insurance and Billing:** For detailed insurance and billing inquiries, contact MD Anderson Cancer Center at 713-792-2991 or 1-800-527-2318 (toll-free).
What insurance does M D Anderson Cancer Center accept?
The University of Texas MD Anderson Cancer Center accepts most insurance plans, excluding Cigna and Health Insurance Exchange Plans. Coverage for treatments may be available for patients enrolled in managed care plans (HMO, PPO, or POS), as well as some Medicare and Medicaid plans. To confirm coverage, contact the hospital directly at 210-450-1000.
What awards or recognition has M D Anderson Cancer Center received?
MD Anderson Cancer Center, located in Houston, Texas, is celebrated for its comprehensive cancer research, including translational, preventative, clinical, and basic science. It is also recognized for its clinical and health services research programs. The center honors exceptional achievements in education and training with awards.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.